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I.
INTRODUCTION
Upon walking into a medical facility, such as a doctor’s office,
the likelihood that an individual will leave with a prescription in
hand is high.1 In 2016 alone, there were approximately 4.45 billion
prescriptions issued throughout the United States (“U.S.”). This was
a significant increase from 3.99 billion prescriptions dispensed six
years earlier.2 The Center for Disease Control and Prevention reported that between 2011 and 2014, 48.9 percent of individuals used
at least one prescription medication in any given 30 day period.3
Trending data seems to indicate that these numbers are growing.4 In
the U.S. and Canada, this excessive prescribing of medication can
be attributed to several factors, including preventative healthcare,
pharmaceutical marketing, and, of course, the actual treatment of a
medical disease or condition.5 With a heavy reliance on the utilization of medications, local pharmacies primarily supply federally approved medications to customers. While federally approved drugs

1

Troyen Brennan, Why Are Physicians Still Prescribing High Cost Brand
Name Drugs? Ask Pharma, REAL CLEAR HEALTH (May 14, 2017),
https://www.realclearhealth.com/articles/2017/05/14/why_are_physicians_still_prescribing
_high_cost_brand_name_drugs_ask_pharma_110590.html; Geoffrey F. Joyce,
Physician Prescribing Behavior and Its Impact on Patient-Level Outcomes,
PUBMED (Sept. 24, 2013), http://pubmedcentralcanada.ca/pmcc/articles/
PMC3782257/.
2
Total Number of Medical Prescriptions Dispensed in the U.S. from 2009
to 2016, STATISTA, https://www.statista.com/statistics/238702/us-total-medicalprescriptions-issued/ (last updated 2019).
3
Therapeutic Drug Use, CDC, https://www.cdc.gov/nchs/fastats/drug-usetherapeutic.htm (last updated May 3, 2017).
4
Id.
5
See Brennan, supra note 1; see also Joyce, supra note 1.
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meet the demands of the population,6 some consumers face challenges in obtaining medications appropriate for specific allergies,
dosages, and other needs.7 This is where the practice of pharmaceutical compounding comes into play.
Traditional pharmaceutical compounding involves the combining of individual pharmacological ingredients with the intent to create a custom medication required by a patient.8 Traditional compounding pharmacies may also modify commercially available
drugs to fit an individual’s needs.9 On the other hand, outsourcing
facilities, while also compounding drugs, differ in the respect that
they do so on a much larger scale.10 These facilities are not necessarily confined to creating personalized compounds for individuals.11 Rather, they may provide compounds to hospitals, long-term
care facilities, and other providers during drug shortages.12
Despite providing citizens with a necessary additional avenue to
acquire medication, safety concerns regarding the general practice
of pharmaceutical compounding have recently been in the spotlight.13 In the U.S., the Food and Drug Administration (“FDA”) determined that state government agencies have not done an adequate
job of inspecting compounding facilities and enforcing required

6

See generally Amanda Baltazar, What is Drug Compounding?, VERY
WELL (Feb. 4, 2017), https://www.verywell.com/what-is-drug-compounding2663861; see also Thomas Wong and Gordon Joseph, Canada’s Provincial Drug
Formulation System, REGULATORY AFFAIRS PROFESSIONALS SOCIETY (Nov.
2011).
7
Id.
8
Robert J. Timko & Philip E. M. Crooker, Pharmaceutical Compounding
or Pharmaceutical Manufacturing: A Regulatory Perspective, 18 INT’L J. OF
PHARMACEUTICAL COMPOUNDING 101, 102 (2014).
9
Id.
10
See generally Michael Werner, Drug Quality and Security Act Gives FDA
Authority to Regulate Drug Compounding and Creates Uniform Federal Standards for Distribution, JDSUPRA (Nov. 19, 2013), https://www.jdsupra.com/legalnews/drug-quality-and-security-act-gives-fda-47575/.
11
Id.
12
Id.
13
Tim Alamenciak, FDA Uncovers Widespread Problems at Compounding
Pharmacies, THE STAR (Apr. 12, 2013), https://www.thestar.com/news/canada/2013/04/12/fda_uncovers_widespread_problems_at_compounding_
pharmacies.html.
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safety precautions.14 As noted by Jane Axelrad, associate director
for policy and head of FDA’s compounding oversight activities,
“[i]t’s really appalling what we’re seeing out there.”15 Axelrad reported that FDA officials have seen unsanitary conditions and other
problems at traditional compounding operations which are primarily
regulated by the states.16 Inspectors have reported such violations as
dead insects, dog beds, dog feces, and hair within close proximity of
sterile compounding areas that could easily result in the contamination of the drugs being produced.17 Additionally, workers have been
observed preparing sterile drug products without first covering their
skin, which can lead to bacterial and particulate contamination.18
Household coffee filters used to filter particulates, toaster ovens
used for sterilization, and kitchen dishwashers and detergent used to
clean sterile compounding equipment represents just a sample of the
darker side of the compounding industry.19 Similarly, Health Canada, the federal institution empowered to oversee drug safety and
regulation, has discovered that compounding companies are slipping
through regulatory cracks maintained by provincial/territorial regulatory bodies.20 While both the U.S. and Canada have initiated actions to ensure consumer-safe pharmaceutical compounds, each
country has taken divergent approaches to accomplish this task.
This article shall serve to explore the regulations created by the
U.S.’ FDA and Canada’s National Association of Pharmacy Regulatory Authorities (“NAPRA”) and the manner in which they affect
the operation of compounding facilities. More specifically, it will
evaluate how these regulations can have a negative impact on both
consumer drug prices and their availability. Part II of this article will
14

Ed Silverman, Safety Issues at Compounding Pharmacy Underscore Oversight Issues, STAT (Apr. 8, 2016), https://www.statnews.com/pharmalot/2016/04/08/compounding-pharmacy-drug-safety-fda/.
15
Kate Traynor, Compounding Oversight a Work in Progress for States,
FDA, AM. SOC’Y OF HEALTH-SYSTEM PHARMACISTS (Mar. 9, 2016),
https://www.ashp.org/news/2016/03/09/compounding_oversight_a_work_in_progress
_for_states__fda.
16
Id.
17
Id.
18
Id.
19
Id.
20
Alamenciak, supra note 13.
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provide a historical background regarding the delegation of regulatory jurisdiction over pharmaceutical compounding in both countries. Part III will summarize the recent federal actions taken by the
U.S. and Canada to resolve compounding safety concerns. Part IV
will compare the FDA’s aim for a centralized regulatory scheme
versus Health Canada’s attempt at maintaining a decentralized regulatory regime. Part V will consider the current and future implications for drug prices and availability that may result from recent federal actions.
II.

BACKGROUND

A.
Pharmaceutical Compounding Regulations in the U.S.
Prior to 2013
In 1938, Congress enacted the Food, Drug, and Cosmetic Act
(“FDCA”), giving the FDA regulatory jurisdiction over the production of new medications.21 However, since compounding fell under
the umbrella of pharmacy practice, the FDA considered the practice
outside its regulatory regime.22 As such, individual states maintained regulatory power over licensing standards and professional
practices for compounding.23
For over fifty years, the FDA deferred to state regulations for
pharmaceutical compounding without any interference.24 In 1992,
an FDA agent reinterpreted the FDA’s regulatory authority under
the FDCA, changing the classification of pharmaceutical compounds to unapproved “new drugs.”25 This reinterpretation caused
widespread panic within pharmaceutical communities.26 The consequences for reclassifying compounds as “new drugs” would have
made the pharmaceutical compounding practice both economically

21

Rebecca J. Riley, The Regulation of Pharmaceutical Compounding and the
Determination of Need: Balancing Access and Autonomy with Patient Safety,
HARVARD
LAW
SCHOOL
(Apr.
2014),
https://dash.harvard.edu/
bitstream/handle/1/8852177/Riley.html?sequence=1.
22
Id.
23
Id.
24
Id.
25
Id.
26
Riley, supra note 21.
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and practicably infeasible.27 If all pharmacy-compounded drugs are
“new drugs,” and therefore considered unlawful, they must first go
through the approval process as specified by the FDA.28 Ultimately,
the U.S. Court of Appeals for the Fifth Circuit affirmed their initial
position from 1938 that pharmacy-compounded drugs were not considered “new drugs”29 requiring prior FDA approval, thereby leaving regulations over pharmaceutical compounds to state governments.30 The implication of this new classification, although overturned, set the stage for a future power struggle between state and
federal government control over pharmaceutical compounding regulations.
Without delineated state regulations for pharmaceutical companies, the difference between compounding and manufacturing
seemed indistinguishable to the FDA.31 This lack of transparency
presented opportunities for pharmaceutical manufacturers to sidestep costly FDA regulations.32 The FDA, in response, issued a Compliance Policy Guide for the “Manufacture, Distribution, and Promotion of Adulterated, Misbranded, or Unapproved New Drugs for
Human Use by State-Licensed Pharmacies” to provide some clarification as to what falls under FDA regulations.33 Although the guide
failed to clearly define what constituted manufacturing, the FDA
newly asserted that it had full discretion over prosecuting what it
believed to be illegitimate compounding practices.34
In 1997, Congress passed the FDA Modernization Act
(“FDAMA”), which provided some broad protections over the production of drug compounds.35 These protections included explicit
exemptions from the FDCA new drug, adulteration, and a misbrand-

27
28
29
30
31
32
33
34
35

Id.
Med. Ctr. Pharmacy v. Mukasey, 536 F.3d 383, 389 (5th Cir. 2008).
Id.
Riley, supra note 21.
Id.
Id.
Id.
Id.
Id.
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ing provision which was specifically aimed at preventing the labeling of drugs in a false or misleading manner.36 Additionally, the
FDAMA provided a specified list of requirements that pharmacies
had to meet in order for a drug to be considered “compounded.”37
One of these requirements is that compounding must be limited to
bulk substances that comply with the U.S. Pharmacopoeia (“USP”)
or the National Formulary (“NF”).38 This was Congress’ first effort
to provide public health protections to consumers of compounded
drugs.39 The Act also required states to enter into a memorandum of
understanding with the FDA to address the inordinate amount of interstate distribution and provide state investigations for complaints.40 This memorandum of understanding (“MOU”) represents
a formal agreement between the FDA and federal, state, or local
government agencies; academic institutions; and other entities.41
The MOU constitutes an understanding between the parties but is a
non-binding agreement.42 The intent of the MOU is to improve consumer protection through the utilization of collective resources.43
Should a state fail to enter into the memorandum, pharmacies residing in that state would be limited to interstate distribution of only
five percent of prescriptions dispensed by a pharmacy.44 By creating
this requirement, Congress maintained FDA regulatory jurisdiction
over pharmaceutical compounding.
The FDA’s authority over compounding once again expanded in
2001, after the U.S. Supreme Court decided Thompson v. Western
States Medical Center. The Supreme Court held that restrictions on
advertising, stated in a provision in FDAMA, violated the First
36

Id.; Labeling Requirements – Misbranding, FDA, https://www.fda.gov/
MedicalDevices/DeviceRegulationandGuidance/Overview/DeviceLabeling/GeneralDeviceLabelingRequirements/ucm052190.htm (last updated Oct. 27,
2017).
37
Riley, supra note 21.
38
Id.
39
Id.
40
Id.
41
FDA Memoranda of Understanding, FDA, https://www.fda.gov/
AboutFDA/PartnershipsCollaborations/MemorandaofUnderstandingMOUs/default.htm (last updated July 17, 2016).
42
Id.
43
Id.
44
Riley, supra note 21.
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Amendment.45 These restrictions included that the prescription be
unsolicited and that the providers not advertise or promote the compounding of any particular drug, class of drug, or type of drug.46
Although the compounding industry gained advertising powers, the
Supreme Court also reinstated the FDCA’s new drug, adulteration,
and misbranding provisions, affirming consumer protection through
accurate and truthful labeling and marketing.47 The Court reasoned
that the reinstatement assisted in “[p]reserving the effectiveness and
integrity of the FDCA’s new drug approval process.”48
Since the Western States Medical Center decision, an outbreak
of meningitis stemming from an improperly compounded sterile
drug prompted the FDA to once again expand its jurisdiction.49 As
a direct response to this incident, the FDA enacted the Drug Quality
and Security Act in 2013.50 As part of this Act, specific steps were
outlined to design and implement an electronic, interoperable system to identify and trace certain prescription drugs as they are distributed in the U.S.51 Moreover, the Act was designed to enhance
the FDA’s ability to help protect consumers from exposure to drugs
that may be counterfeit, stolen, contaminated, or otherwise harmful.52

45

See Thompson v. W. States Med. Ctr., 122 S. Ct. 1497, 1508‒09 (2002).
Id. at 1502‒03.
47
See id. at 1508‒09.
48
Id. at 1505.
49
Rachel M. Smith et al., Estimated Deaths and Illnesses Averted During
Fungal Meningitis Outbreak Associated with Contaminated Steroid Injections,
United States, 2012–2013, 21 EMERGING INFECTIOUS DISEASES 933, 934 (June 6,
2015), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451895/.
50
Drug Quality and Security Act, Pub. L. No. 113-54 (2013),
https://www.congress.gov/bill/113th-congress/house-bill/3204.
51
Drug Supply Chain Act, FDA, https://www.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/DrugSupplyChainSecurityAct/
(last updated Nov. 28, 2017); see also Margaret A. Hamburg, New Law Enhances
Safety of Compounded Drugs and Protection of the Drug Supply Chain, FDA
VOICE (Dec. 2, 2013), https://blogs.fda.gov/fdavoice/index.php/2013/12/newlaw-enhances-safety-of-compounded-drugs-and-protection-of-the-drug-supplychain/.
52
Id.
46
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B.
Pharmaceutical Compounding Regulations in Canada
Prior to 2016
In 1920, Canada’s FDA equivalent, the Federal Department of
Health enacted the Food and Drugs Act to regulate the production,
sale, and importation of food, drugs, cosmetic, and medical devices.53 Additionally, by the late 1920s, the Food and Drugs Regulations were created to set the standards for the “composition,
strength, potency, quality, or other property of [an] article of food or
drug.”54 However, much like in the U.S., the Food and Drug Act and
Regulations provided federal regulatory power over drug manufacturers but not compounding pharmacies.55 This distinction was not
clarified until 2000, when Health Canada published a policy titled
“Manufacturing and Compounding Drug Products in Canada.”56
The aim of this policy was to better regulate the process federal regulators, provincial/territorial regulators, and healthcare professionals must follow when dealing with jurisdictional issues related to
compounding and manufacturing.57 The guiding principle of this
policy maintained that compounding must be a legitimate part of the
practice of regulated healthcare professionals and must not be used
to bypass the federal drug review and approval system.58 The adoption of this policy would enable a consistent Canada-wide approach
to ensure that all products and activities are appropriately regulated.59

53

Frequently Asked Questions – Food and Drug Regulations, GOV’T OF
CANADA (June 27, 2016), https://www.canada.ca/en/health-canada/corporate/about-health-canada/legislation-guidelines/acts-regulations/frequentlyasked-questions-food-drug-regulations.html; see also Food and Drugs Act, R.S.C.
1985, c. F-27 (Can.).
54
Id.
55
Health Products and Food Branch Inspectorate, Policy on Manufacturing
and Compounding Drug Products in Canada, GOV’T OF CANADA (Jan. 26, 2009),
https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-manufacturing-practices/guidance-documents/policymanufacturing-compounding-drug-products.html.
56
Id.
57
Id.
58
Id.
59
Id.
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In 2009, the Health Products and Food Branch Inspectorate provided additional clarification, publishing an administrative document noting the distinction between manufacturing and compounding.60 Regulatory jurisdiction for pharmaceutical compounding was
delegated to provinces/territories.61 Health Canada reasoned that
compounding is a licensed act that falls within the scope of pharmacy practice.62 As such, any professional engaged in the compounding process must comply with individual province/territory licensing regulations.63 With compliance being met, the risk involved
in compounding falls entirely on health professionals.64
To the contrary, pharmaceutical companies that are deemed
“manufacturers” must comply with more restrictive federal regulations.65 In order for a company to sell a manufactured drug, Health
Canada must review the product’s quality, safety, and efficacy.66
Moreover, manufactured drugs require a Drug Identification Number and/or Notice of Compliance in order to be sold.67 These additional regulations reduce the production of dangerous or otherwise
unsatisfactory drugs.68
Should there be any uncertainty as to whether drug production
can be clearly categorized as manufacturing or compounding, a discussion between the federal government and provincial/territorial
bodies takes place to make a final determination.69 Yet, because
each decision is decided on a case-by-case basis,70 some manufacturing activity may be incorrectly categorized as compounding and
thus, bypass certain safety standards. This has ultimately led to a
number of large scale health issues.71 For example, in an incident
60

Id.
Id.
62
Id.
63
Id.
64
Id.
65
Id.
66
Id.
67
Id.
68
Id.
69
Id.
70
Id.
71
Amina Zafar, Chemotherapy Outsourcing Done by Hospitals Across Canada, CBC NEWS (Apr. 25, 2013), http://www.cbc.ca/news/health/chemotherapyoutsourcing-done-by-hospitals-across-canada-1.1308762.
61
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that left 1200 patients in New Brunswick and Ontario with lowerthan-expected dosages of the cancer drug Gemcitabine, hospitals in
at least three Canadian provinces revealed that they outsourced their
chemotherapy preparations through compounding facilities.72 As a
result, Health Canada is attempting to establish uniform safety
standards that provinces/territories will be required to individually
adopt and implement.73
III.

SUMMARY OF THE CHANGES IN FEDERAL REGULATIONS FOR
PHARMACEUTICAL COMPOUNDING IN THE U.S. AND CANADA
To understand how the newly implemented regulatory schemes
for pharmaceutical compounding between the U.S. and Canada diverge, it is important to first carefully analyze each scheme independently.
A.

U.S. Drug Quality and Security Act
When a New England pharmaceutical compounding company in
Framingham, Massachusetts produced a tainted steroid medication
that resulted in a deadly meningitis outbreak, the FDA made the decision to intervene.74 The outbreak led to 64 deaths and 751 nonlethal injuries.75 As a direct response to this incident, the FDA created and enacted the Drug Quality and Security Act.76 The Drug
Quality and Security Act amended the Food, Drugs, and Cosmetics
Act (“FDCA”), granting the FDA additional authority to regulate

72

Id.
Model Standards of Pharmacy Compounding of Non-Hazardous Sterile
Preparations, NAPRA (Nov. 1, 2016), https://napra.ca/sites/default/files/201709/Mdl_Stnds_Pharmacy_Compounding_NonHazardous_Sterile_Preparations_Nov2016_Revised_b.pdf.
74
Rachel M. Smith et al., Estimated Deaths and Illnesses Averted During
Fungal Meningitis Outbreak Associated with Contaminated Steroid Injections,
United States, 2012–2013, 21 EMERGING INFECTIOUS DISEASES 933, 934 (June 6,
2015), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451895/.
75
Multistate Outbreak of Fungal Meningitis and Other Infections – Case
Count, CTR. FOR DISEASE CONTROL AND PREVENTION (Oct. 30, 2015),
https://www.cdc.gov/hai/outbreaks/meningitis-map-large.html.
76
Drug Quality and Security Act, Pub. L. No. 113-54 (2013).
73
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the manufacturing of sterile pharmaceutical compounds.77 Specifically, Section 503A of the FDCA was amended to regulate traditional compounders.78 The Drug Quality and Security Act also implemented a new provision, Section 503B, to regulate larger outsourcing drug facilities.79
Section 503B allows compounders to voluntarily register as an
outsourcing facility, which provides exemptions from FDA approval and labeling requirements.80 In addition, registering as an
outsourcing facility allows for the compounding of drugs without
patient-specific prescriptions.81 While it would seem that most companies would be disposed to register as an outsourcing facility, there
are a considerable number of disadvantages. Outsourcing facilities
are required to pay an FDA imposed annual registration fee of over
$15,000.82 The compounder is then subjected to federal inspections
on a “risk-based” schedule.83 Due to the FDA’s extremely strict regulations, registered outsourcing facilities may be required to pay reinspection fees of over $15,000 if noncompliance is identified.84 Additionally, outsourcing facilities must also comply with the U.S.
Food and Drug Administration’s Current Good Manufacturing Prac-

77

Id.
Examining Implementation of the Compounding Quality Act, U.S. FOOD
AND DRUG ADMIN. (Jan. 30, 2018), https://www.fda.gov/NewsEvents/Testimony/ucm594297.htm.
79
Information for Outsourcing Facilities, U.S. FOOD AND DRUG ADMIN.,
https://www.fda.gov/Drugs/
GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm393571.htm. (last visited Mar. 18, 2019).
80
Id.
81
Information Concerning Outsourcing Facilities Registration, U.S. FOOD
AND DRUG ADMIN., https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm389118.htm. (last visited Mar. 18,
2019).
82
Human Drug Compounding Outsourcing Facility Fees, U.S. FOOD AND
DRUG ADMIN., https://www.fda.gov/ForIndustry/UserFees/HumanOutsourcingFacilityUserFee/default.htm. (last visited Mar. 18, 2019).
83
Id.
84
Id.
78
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tice (“CGMP”) regulations when producing pharmaceutical compounds.85 The CGMP requirements utilize the same strict regulations used by the FDA for approving drugs.86 Systems must be put
into place to assure proper design, monitoring, and control of manufacturing processes and facilities.87 However, adherence to the
CGMP regulations, while assuring the identity, strength, quality,
and purity of the drug,88 drives production costs up.89 This is further
exacerbated by the expense of extensive monitoring, documentation, and reporting.90
Should the compounding facility opt not to register as an outsourcing facility, it will be governed by 503A and state regulations.91 While quality assurance standards are similar to those required in 503B, the individual prescription mandate in 503A prevents traditional compounding pharmacies from compounding
products in large quantities.92 Section 503A limits traditional compounding pharmacies to stocking no more than a 30-day supply of
any specific compounded drug.93 This can be problematic as pharmacists must rely on past transactions with consumers as a measure

85

Information for Outsourcing Facilities, supra note 79.
Facts About the Current Good Manufacturing Practices (CGMPs), U.S.
FOOD AND DRUG ADMIN., https://www.fda.gov/drugs/developmentapprovalprocess/manufacturing/ucm169105.htm. (last visited Mar. 18, 2019).
87
Id.
88
Id.
89
See Stricter Drug Compounding Regulations Complicate Ophthalmology
Care, HEALIO (Oct. 10, 2017), https://www.healio.com/ophthalmology/regulatory-legislative/news/print/ocular-surgery-news/%7B820dbc2e-6e7c-48d7-b7a301e75097f434%7D/stricter-drug-compounding-regulations-complicate-ophthalmology-care?page=1.
90
Id.; see generally Center for Drug Evaluation and Research: Outsourcing
Facility Information, FDA (Sept. 2017), https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/UCM577334.pdf.
91
Examining Implementation of the Compounding Quality Act, supra note
78.
92
Prescription Requirement Under Section 503A of the Federal Food, Drug,
and Cosmetic Act: Guidance for Industry, FDA (Dec. 2016),
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/UCM496286.pdf.
93
Id.
86
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to predict the quantities of each drug necessary to meet future demand.
With a higher cost of production and smaller supply of products,
traditional compounding pharmacies may be forced out of the market. Furthermore, with the FDA encouraging state enforcement initiatives, traditional compounding pharmacies risk being fined for
producing drugs in excess due to innocent or incorrect calculations
for future demand.
B.

Canada’s Model Standards for Pharmacy Compounding
Similar to the U.S., a health crisis resulted in the restructuring of
drug compounding regulations in Canada. After the 2013 incident
in which 1,200 people in Ontario and New Brunswick received
lower-than-intended doses of chemotherapy,94 Ontario amended
provincial regulations to prevent this type of incident from being
repeated.95 Canada clearly needed higher and uniform standards for
compounding drugs.96 As a result, the NAPRA instituted the Model
Standards for Pharmacy Compounding.97 The Model Standards provide the minimum requirements to be applied in each province/territory.98 It is important to note that these Model Standards are comprised of three phases implemented over a four year period of time.99
The initial 2016 release of these national standards for compounding
preparations is scheduled to be fully phased in by 2021.100 Canadian
pharmaceutical compounders will be encouraged to follow the fouryear phased in approach to ensure they meet all requirements by
94

Zafar, supra note 71.
See generally Jake J. Thiessen, A Review of the Oncology Under-Dosing
Incident, ONTARIO MINISTRY OF HEALTH AND LONG-TERM CARE (July 12, 2013),
http://www.health.gov.on.ca/en/public/programs/cancer/drugsupply/docs/
report_thiessen_oncology_under-dosing.pdf.
96
See id.
97
See id.
98
Bob Nakagawa, 125th Anniversary Conference and Gala: The Future of
Pharmacy, C. OF PHARMACISTS OF BRIT. COLUMBIA (Sept. 17, 2016), http://library.bcpharmacists.org/5_Programs/5-3_PDAP/5197CPBC125_PowerPoint.pdf.
99
Implementing the New Model Standards For Pharmacy Compounding, C.
OF PHARMACISTS OF BRIT. COLUMBIA, http://www.bcpharmacists.org/compounding (last visited Mar. 25, 2019).
100
Id.
95
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May 2021, when the new bylaws become fully effective.101 Should
any compounding manufacturer repeatedly fail to meet these standards, a decision will have to be made regarding permanent termination of sterile compounding preparation.102
The NAPRA has released the three subsections for Model Standards for Pharmacy Compounding.103 The three subsections consist
of Model Standards for Non-Hazardous Sterile Preparation, Hazardous Sterile Preparations, and Non-Sterile Preparations.104 With consideration to commercial compounding, the NAPRA has implemented stricter regulations regarding personnel handling and supervision of the production of compounded drugs; policies and procedures; facility design and required equipment; and general maintenance logs.105 As an example, the Model Standards specify more
stringent requirements depending on the complexity and risk of the
compounding activity, the use of hazardous products in the production, and workflow.106

101

Id.
Model Standards for Pharmacy Compounding of Hazardous Sterile Preparations, NAPRA (Nov. 1, 2016), http://napra.ca/sites/default/files/201709/Mdl_Stnds_Pharmacy_Compounding_Hazardous_Sterile
_Preparations_Nov2016_Revised_b.pdf.
103
Id.; see also Model Standards for Pharmacy Compounding of Non- Sterile
Preparations, NAPRA (Mar. 28, 2018), NAPRA, https://napra.ca/sites/default/files/documents/Mdl_Stnds_Pharmacy_Compounding_Nonsterile_
Preparations_March2018_FINAL.pdf.
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CENTRALIZED VERSUS DECENTRALIZED REGULATORY
FRAMEWORKS

A.

State Oversight of Compounding Pharmacies
With the meningitis outbreak instilling panic within the general
population in 2012, the U.S. federal government began investigating
compounding pharmacies searching for safety violations.107 While
the FDA has issued warnings and recommendations identifying specific safety violations, the identified compounders and states refuse
to accept the FDA as having ultimate authority in regards to pharmacy practice.108 Although the Drug Quality and Security Act allows the FDA to inspect facilities and enforce regulations, the overlap between state and federal regulations, in addition to the disagreements between regulators, has resulted in confusion and a lack of
accountability.109
State regulations, not being as rigorous as FDA regulations, have
become the crux of ineffective government regulation.110 An analysis by PEW Charitable Trusts, a public policy organization, determined that approximately only half of the states require compounding pharmacies that produce sterile medications to fully comply with
recognized quality standards.111 Furthermore, the PEW Charitable
Trust states that there is great variability between the breadth of USP
797 requirements, which are the recognized and accepted quality
standards, and enforcement between states.112 “Regarding compounding inspector qualifications, only 70% of the states required a
pharmacist license, only 60% required prior experience within a
pharmacy, and only 58% required training on applicable USP standards.”113 It is an alarming issue that twenty-eight out of forty-three
107
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respondents to the PEW survey did not require specialized training
in the compounding of sterile medication.114
Discrepancies between the FDA and the Texas State Board of
Pharmacy, in regulating compounding pharmaceutical manufacturers, illuminates the potential conflicts and confusion between the
two regulatory schemes.115 In 2016, the FDA “uncovered multiple
egregious, life-threatening problems in a compounding pharmacy’s
process for making sterile drugs.”116 However, the FDA remains
powerless to force the compounder to abide by any safety recommendations.117 In response to the FDA’s allegations along with Public Citizen’s, a consumer advocacy group, plea to suspend the compounder’s license, the Texas State Board of Pharmacy sent its own
inspector to investigate the matter.118 The state inspector determined
that the compounder, IV Specialty, was properly abiding by state
regulations and that the public was not in any imminent danger.119
As such, the Texas State Board of Pharmacy refused to halt the compounder’s production, issue a recall of drugs manufactured and delivered, or suspend the compounder’s license as recommended by
the FDA and Public Citizen.120
Apart from the varying quality standards between states, sixty
percent of states of the forty-three responding states to the PEW survey do not require compounding pharmacies to track and report adverse events.121 Additionally, compounding activity in sixteen states
is completely unsupervised by state regulators.122 Of the forty-three
responding states, only fifty-three percent actually conduct annual
routine inspections of compounding facilities creating sterile
drugs.123 Should any safety issue be identified during the routine annual inspection, a written response from the pharmacy describing
how the issues were remediated would be required.124 However,
114
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only two-thirds of the surveyed states conduct a follow-up inspection to ensure compliance.125 It is this lack of accountability that results in egregious violations and provides the potential for the distribution of hazardous drugs.
The Pharmacy Compounding Accreditation Board (PCAB) assesses pharmacies that compound medication, ensuring their compliance with U.S. Pharmacopeial Convention guidelines, which reduces safety risks.126 However, compounding pharmacies are not required by states to be accredited by the PCAB, thereby removing a
necessary level of protection for public health.127
This variation in state oversight has raised questions regarding
state regulators’ ability to protect public health and has prompted
Congress to consider granting the FDA even more regulatory authority over the compounding industry.128
B.
U.S. FDA’s Aim Towards Centralized Regulation for
Compounding Drugs
The lack of specificity within sections 503A and 503B of the
Compounding Quality Act has left the door open for considerable
misinterpretation.129 The main issue is that state laws and regulations are not aligned with federal laws and regulations.130 States vary
on how they define an outsourcing facility and therefore, may fail to
properly recognize and report an outsourcing facility to the FDA.131
New York, for example, has updated statutes and regulations to include a definition and category for outsourcing facilities.132 Other
states, however, categorize outsourcing facilities with compounding
pharmacies, manufacturers, or distributors, which allows these
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states to maintain control over their outsourcing facilities.133 Because Congress, in the creation of section 503B, did not mandate
that outsourcing facilities register with the FDA, the FDA lacks effective regulation.134 This lack of control allows for safety violations
by compounding facilities, causing public health issues.135
While the FDA attempts to entice compounders to register as an
outsourcing facility by providing incentives, including bypassing
the prescription requirement in 503A, state regulators negate these
incentives.136 As a number of states have no specific guidelines to
handle 503A federal violations, they ultimately permit traditional
compounding pharmacies to compound without individual patient
prescriptions.137 Currently, nine states have no intent to discipline
pharmaceutical manufacturing violators or require these compounding pharmacies to register as outsourcing facilities with the FDA.138
Once again, accountability seems to be absent. As such, only 73 out
of 1,500 compounding pharmacies have registered as of December
8, 2017.139
While the FDA has the authority to take legal action against sterile compounding pharmacies that are allegedly conducting unsafe
practices, it has rarely done so and remains cautious about overstepping state authority.140 Furthermore, although the FDA has been aggressively inspecting compounding pharmacies, it relies on communication with state regulators regarding serious adverse events and
quality problems reports.141 As noted above, with sixty-three percent
133
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of forty-three states not requiring compounders to track and report
adverse events, the FDA has little knowledge and is therefore, limited in its ability to protect public health.142
With ineffective state oversight over compounding pharmacies
and enforcement of the Drug Quality and Security Act, the FDA has
requested greater jurisdiction over sterile compounded drugs.143
Moreover, the Biotechnology Innovations Organization (“BIO”),
The Pharmaceutical Research and Manufacturers of America
(“PhRMA”), PEW Charitable Trusts and other groups sent letters
urging Congress to provide the FDA with additional oversight authority over drug compounders.144 These organizations stress that
“[i]f [the] FDA is not permitted to maintain that line between traditional compounding and outsourcing facilities, patients are put at
risk, states and compounding pharmacies will not have clear regulatory guidance, and the lessons of the national meningitis outbreak
will have been forgotten.”145
Fairleigh Dickinson University School of Pharmacy and Health
Sciences has published a list of ten recommendations to improve the
quality and ensure the safety of compounded drugs. The top three
recommendations provide the FDA with additional authority over
facilities producing sterile compounds. The three are as follows:
1. Congressional legislation removing ambiguity from provisions of section 503A and empowering the FDA to enforce 503A.146
2. Congressional legislation that requires outsourcing facilities
to register with the FDA, thereby, mandating operations under
CGMP requirements. Such action will allow inspection of such facilities to be governed by the FDA (rather than pharmacy licensing
boards), which has the potential to drive closure of the sterile compounding facilities not in compliance.147
142
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3. Congressional legislation that mandates adverse event reporting and complete product labeling by all compounding pharmacies, not just registered outsourcing facilities.148
Although these are nothing more than recommendations, the
combination of this publication and the letters sent to Congress by
the BIO, PhRMA, PEW, and the other organizations illustrates the
overall agreement that a more centralized regulatory framework
needs to be implemented. However, with the overarching concern
regarding the separation of powers, the time it may take to enact
these recommendations may be well after the occurrence of another
health crisis caused by unsafe compounded medications. Until Congress provides additional clarity for state and federal regulators, consumers of compounded drugs remain extremely vulnerable.
C.

Proposed Legislation and State Pushback
As recently as June 2017, a new bill sponsored by Congressmen
H. Morgan Griffith (R-VA) and Henry Cuellar (D-TX) was proposed that would certainly weaken consumer protection.149 This bill
would permit “traditional compounding pharmacies to distribute
compounded drugs within a state without requiring an individual
prescription (only a ‘drug order’) and without being required to follow CGMP standards as [is required by] outsourcing facilities . . . .”150 If passed, the bill would attenuate the 2013 law that
created outsourcing procedures and guidelines.151 Compounding
companies would be able to continue producing pharmaceuticals
without having to register, without having to report adverse events,
and without having to pay the user fees that are required with registering as an outsourcing facility.152 More importantly, compounding
pharmacies would not be required to follow CGMP standards,
148
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thereby saving costly expenses.153 The potential of this bill could be
catastrophic, taking the industry back to pre-2013 standards and recreating conditions that could result in outbreaks similar to that which
occurred with the New England Compounding Center.154 It is no
surprise that HR2871 is strongly supported by the International
Academy of Compounding Pharmacists, a trade group that donated
to both Griffith’s and Cuellar’s political campaign.155 With all the
latitude and lower costs this bill would afford compounding companies, it would behoove these companies to support such legislation,
irrespective of the potential consequences.
D.
Health Canada so Far Maintains a Decentralized
Regulatory Scheme
Unlike U.S. states, which take pride in considering themselves
the “laboratories of democracy,”156 Canada has been working on resolving its national unity crisis by attempting to establish provincial
equality.157 Provincial equality pertains to jurisdictional control, political representation, and economic equality.158 Simply put, Canadian provinces are focused on making sure policies extended by the
federal government and their outcomes are proportionally equal
within each province. As long as a federal policy promotes uniformity, provinces are more open to accepting and enforcing that
policy, especially when it is not politicized.
A recent ISMP Canada Safety Bulletin makes clear the present
state of the compounding industry.159 Canadian patients diagnosed
153
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with cancer have the option of choosing alternative medical approaches, including naturopathy, for treatment of their conditions.160
In one incident, reported as recently as January 2018, a cancer patient was prescribed a tissue and wound healing formulation for
postsurgical healing support.161 The formulation was administered
intravenously and contained selenium prepared by a compounding
pharmacy.162 Upon hospital discharge, after surgical excision of a
cancerous tumor and subsequent to the administration of the selenium formulation, the patient began to experience hypotension,
shortness of breath, and chest pain and ultimately passed away.163
Postmortem investigations revealed that the selenium concentration
in the infused formula was one thousand times greater than intended,
which likely contributed to the patient’s death.164
In another incident, after 1,200 people received lower-than-intended doses of chemotherapy in New Brunswick and Ontario,165
Canada’s federal and provincial/territorial governments became
concerned with the manner in which to protect the public health
from unsafe compounded drugs.166 The Ontario Ministry of Health
and Long-Term Care commissioned Dr. Jake Thiessen, a pharmacokinetic specialist, as an independent investigator to determine the
cause of the incident and provide recommendations.167 In Dr. Thiessen’s report, he pointed out that the vendor who produced the doses
of chemotherapy provided inter-provincial services because both
New Brunswick and Ontario hospitals were affected.168 As such,
provinces and territories throughout Canada were at risk of experiencing similar incidents unless changes were made on a national
scale.169 One of Dr. Thiessen’s recommendations provided that the
160
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NAPRA work closely with Health Canada as a means of creating
the best objective standards for sterile and non-sterile product preparation within a licensing pharmacy.170
Dr. Thiessen’s recommendation to look to the NAPRA essentially made the public health issue revolving around pharmaceutical
compounding less politicized. The NAPRA is comprised of members from each province and territory that are represented on the association’s board of directors.171 With each provincial and territorial
regulatory body collaborating, the NAPRA has successfully published three subsections of the Model Standards for Pharmacy Compounding to be adopted on a national basis.172 As such, provinces
and territories continue to retain full control over compounding activity, thereby resolving international unity issues and maintaining a
consistent approach.
E.
The NAPRA Model Standards Increase Accountability
Within the Pharmacies
The NAPRA Model Standards for Pharmacy Compounding is a
comprehensive set of regulations designed to increase safety standards for the preparation of sterile and non-sterile compounded
drugs.173 In contrast to the U.S., where Congress granted the FDA
regulatory authority to oversee compounding pharmacies,174 the
NAPRA Model Standards preserves the authority of ensuring the

170

Id.
NAPRA Governance, NAPRA, http://napra.ca/napra-governance (last visited Mar. 7, 2019).
172
Model Standards for Pharmacy Compounding of Hazardous Sterile Preparations, NAPRA (Nov. 1, 2016), http://napra.ca/sites/default/files/201709/Mdl_Stnds_Pharmacy_Compounding_Hazardous_Sterile
_Preparations_Nov2016_Revised_b.pdf; Model Standards for Pharmacy Compounding of Non-Hazardous Sterile Preparations, NAPRA (Nov. 1, 2016),
NAPRA,
https://napra.ca/sites/default/files/2017-09/Mdl_Stnds_Pharmacy_Compounding_NonHazardous
_Sterile_Preparations_Nov2016_Revised_b.pdf; Model Standards for Pharmacy Compounding of Non- Sterile Preparations, NAPRA (Mar. 28, 2018), NAPRA, https://napra.ca/sites/default/files/documents/Mdl_Stnds_Pharmacy_Compounding_Nonsterile_Preparations_March2018_FINAL.pdf.
173
Implementing the New Model Standards For Pharmacy Compounding, supra note 99.
174
Silverman, supra note 14.
171

2019]

UNIVERSITY OF MIAMI INTER-AMERICAN LAW REVIEW

169

safe preparations of compounded drugs solely within the provincial/territorial regulatory authorities.175 Luckily, the NAPRA Model
Standards vastly raises the criteria for hiring personnel, enforcing
policies and procedures, ensuring clean facilities and proper equipment, and keeping a general maintenance log.176 Adoption of the
Model Standards should make provincial/territorial oversight easier
and lower the risk of public health issues.
With regards to personnel involved with sterile preparations, including pharmacists, pharmacist technicians, and pharmacist assistants, each individual must attain the appropriate education, experience, and required trainings and assessments in order to participate
in the process of compounding of sterile preparations.177 The training and assessments include the following:
[R]eading and understanding the policies and procedures related to compounded sterile preparations;
theoretical training, with assessment covering various topics . . . ; individual practice training and assessment in the workplace clean room . . . ; assessment of aseptic techniques, based on gloved fingertip
sampling (GFS) and media fill tests, for various types
of sterile preparations to be compounded.178
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Trainings and assessments must be complete at least once a year
in the work place for personnel operating at low or medium risk levels and at least twice a year for preparation with high risk levels.179
Should any compounding personnel fail an assessment, the work
shall be immediately halted and retraining will be required.180 All
assessments and trainings are recorded in each employee’s file and
must be retained for a period specific to the provincial/territorial authority.181
Pharmacies conducting sterile preparation require an on-site
sterile compounding supervisor, separate from a pharmacy manager
or department head.182 The sterile compounding supervisor ensures
that requirements by the Model Standards are met and all records
are available for audit and inspection by provincial/territorial authorities.183
One of the main responsibilities for a sterile compounding supervisor is to establish the content for all policies and procedures.184
Further, the content must provide a detailed description of all activities occurring in the pharmacy.185 Procedures must be clear and
concise, follow a standard format, and include an index for easy access.186 Established policies and procedures must be promptly updated should there be a change in practice or standards.187 Even
without changes, policies and procedures must be reviewed every
three years by the sterile compounding supervisor.188 If the compounding of a drug is prepared by more than one pharmacy, as permitted by provincial/territorial legislation, the dispensing pharmacy
should include information about the acquisition of compounded
sterile preparations for patients in its policies and procedures.189
179
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Compliance with the policies and procedures prescribed by the sterile compounding supervisor ensures proper quality and safety of the
prepared drugs.
The Model Standards for Compounding of Non-Sterile Preparations similarly follow suit as a means of increasing accountability
within compounding facilities. Along with the specified training and
assessment of personnel, specialized equipment, and policies and
procedures for quality assurance, Non-Sterile Preparations specifically require that a risk assessment be completed prior to compounding to identify the appropriate level of requirements to minimize
contamination of each compounded product and provide adequate
protection for personnel.190 There are three levels of requirements,
Level A, B, and C, where compounded drugs are categorized by how
the product is defined under the USP General Chapter <795>, the
quantity of ingredients being compounded, and whether the product
is hazardous.191 Level A has the lowest requirement, requiring only
a separate space designated for compounding. However, Level B
and C have more stringent requirements. For example, one of the
requirements under Level C is a well-ventilated room with appropriate air exchange and negative pressure.192 Even though accountability may seem lower for certain non-sterile compounded drugs,
such as simple and moderate compounds categorized as Level A,
public threat is lessened for non-sterile compounded drugs based on
the modality of consumer administration (i.e. oral vs. injectable).193
Regardless, by conducting a risk assessment in compliance with the
NAPRA Model Standards, consumers of non-sterile compounded
drugs are better protected from incurring health problems.
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As a whole, the NAPRA Model Standards increase accountability within compounding pharmacies by requiring general maintenance logs.194 These records include either computerized or paper
documentation regarding activities such as cleaning and disinfecting, certification and maintenance of the facility, risk assessment,
and certification of the primary engineering control and maintenance of other equipment.195 Verification of proper operation of
equipment and instruments (i.e. calibration, temperatures for different types of storage) must be documented.196 All general maintenance logs must be retained according to the respective provincial/territorial authority, thus allowing provinces/territories to ensure that compounding facilities remain in compliance with these
enhanced safety standards.197
Through the implementation of these three subsections of the
NAPRA Model Standards for Compounding, the combination of
oversight by provincial/territorial authorities and accountability by
the pharmacies should be effective in ensuring safe compounding.
F.

Canada’s Possible Future Regulatory Disaster
While the NAPRA Model Standards for Pharmacy Compounding provide the framework for safe preparation, Canada now seems
to be revisiting Dr. Thiessen’s recommendations. Recently, Health
Canada initiated a regulatory initiative to create a new framework
for addressing commercial compounding.198 Current “Policy on
194
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Manufacturing and Compounding Drug Products in Canada” defines the difference between manufacturing and compounding in order to determine whether an activity is provincially/territorially or
federally regulated.199 However, without concise regulatory oversight, a gap remains, creating public health issues.200
For Health Canada, there are inherent reasons to justify a cautious approach to this new regulatory initiative. Prior to creating the
Model Standards for Pharmacy Compounding, Canada closely followed the U.S. guidelines and policies for compounding drug products.201 This is exemplified by Canada’s “Policy on Manufacturing
and Compounding Drug Products in Canada” that addresses the notion that pharmaceutical compounding is not a means of bypassing
federal drug review and approval systems.202 More specifically,
compounded drug products must result in a customized medication
that does not duplicate an existing federally approved drug.203
Health Canada also utilizes the U.S. Pharmacopoeia guidelines for
the preparation of sterile and non-sterile compounds.204 While following U.S. guidelines has not been detrimental to Canada’s regulatory framework thus far, should Health Canada continue to pursue
the U.S.’ currently enacted Compounding Quality Act, regulatory
loopholes may arise.
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CURRENT AND FUTURE IMPLICATIONS ON PRICES AND
AVAILABILITY OF DRUG COMPOUNDS

A.

United States
While the production of safe compounded drugs remains a top
priority for the FDA, the Drug Quality and Security Act has made it
less financially feasible for traditional compounding pharmacies to
be profitable in the market.205 Operating with lower profits, several
pharmaceutical compounding companies have been forced to reduce
the number of drugs produced.206 Leiter’s Compounding Pharmacy,
at one time producing an astonishing 1,800 drugs, was compelled to
lower production to only 11 drugs due to new FDA restrictions.207
In addition, compounding pharmaceutical companies have been obligated to employ fifteen to twenty quality assurance staff members
to ensure compliance with the stricter regulations.208 The combination of reducing the number of drugs produced,209 hiring additional
employees,210 and producing compounded drugs in small quantities
due to rigid prescription requirements,211 has driven up the cost of
production tremendously.212
Ultimately, consumers are the ones paying the price as many
compounded drugs will be either unavailable or are priced out of the
reach of those that need them.213 According to Charles Leiter, owner
of Leiter’s Compounding Pharmacy, physicians are finding it difficult to obtain medications necessary to treat their patients.214 In par205
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ticular, Avastin utilized by retina physicians has been nearly impossible to acquire.215 Avastin, an FDA approved medication used as a
chemotherapeutic treatment for colon cancer, has also been successfully used for diseases such as macular degeneration, retinal vascular disease, and diabetic retinopathy.216 In creating proper doses for
retinal usage, compounding pharmacies must divide a four milliliter
marketed dose into sixty single-use doses with each dose costing
patients sixty dollars.217 However, due to FDA enforcement and the
prescription requirement under section 503A, many compounding
pharmacies have stopped offering Avastin making it practically unavailable.218 Without the compounding pharmacies’ offerings of
Avastin, patients are left with two FDA approved drugs, Lucentis
and Eylea, costing approximately $2,020 and $1,950 respectively.219
In such cases, many patients, with or without insurance, simply cannot afford the exorbitantly expensive medications, while viable
medications costing 97 percent less than their FDA approved counterparts are simply unavailable due to government overregulation.220
Simply stated, in the government’s efforts to protect consumers
through strict regulation and requirements, smaller compounding
companies are unable to comply due to the high costs of meeting
those requirements and are penalized to the point that consumers
lose their access to needed medications.221
On January 4, 2018, the FDA announced that the USP standards
are currently under revision with the intent of raising the standards
for drug compounding production.222 All compounding pharmacies
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under 503A will be required to implement the USP’s revised standards.223 Although there is no indication as to the manner in which
the USP standards will be modified, it is reasonable to assume that
pharmacists will need to be retrained and be reassessed to prove
competency. Furthermore, compounding pharmacies may be required to purchase new or additional equipment to ensure the safe
preparation of sterile drug compounds. While a safer product is potentially in our future, the additional requirements placed on compounders may cause an economic burden so great as to cause smaller
compounding pharmacies to close shop.
Additionally, should Congress amend the Compounding Quality
Act, mandating outsourcing facilities to register with the FDA, those
outsourcing facilities may choose to close their doors as well. For
exemption from the prescription requirement in section 503A, outsourcing facilities need to meet the following criteria:
1. The outsourcing facility is in compliance with CGMPs.224
2. A compounded drug can not contain bulk drug substances
unless the substance appears on a list established by the secretary
when there are clinical needs.225
3. Ingredients (other than bulk substances) used in compounds
must comply with standards of the USP, NF, or of another compendium.226
4. The drug does not appear on a list published by the Secretary
because it’s unsafe or ineffective.227
5. The drug is not an “essential copy” of one or more approved
drugs.228
6. The drug doesn’t present demonstrable difficulties for compounding.229
7. The outsourcing facility has a proper control system when
dealing with compounded drugs or ingredients that are subject to the
FDA’s risk evaluation and mitigation strategy.230
223
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8. The outsourcing facility that compounds the drug is the only
entity that can sell the drug.231
9. The drug must be labeled appropriately.232
The difficulty in meeting these requirements is obvious as the
FDA has issued warning letters to eight out of the seventy-three registered outsourcing facilities, stating that they are failing to meet the
requirements under section 503B.233 The FDA has also ordered two
facilities to cease sterile operations and recall dispensed sterile products.234 The combination of increased FDA scrutiny along with significant increases, approximately five to ten times, in costs to
achieve the CGMP requirements,235 has outsourcing facilities questioning whether the financial investment is worth making. As a result, with massive shortages of over 300 essential drugs, in which
outsourcing facilities normally assist in meeting those needs,236 conditions will continue to deteriorate and leave patients without medications to treat their ailments.
Should the U.S. maintain its narrow and single approach towards
public health protections, patients will no longer have access to effective and affordable treatments. As such, federal and state laws
and regulations need modification to not only ensure the safety of
compounded drugs, but to ensure drug availability with reasonable
consumer costs. Creating a system of uniform accountability between states, along with shifting some responsibility to the compounding companies in a similar fashion to NAPRA Model Standards, may be an effective way to accomplish this balance. The more
stringent FDA restriction created through the Compounding Quality
Act does not seem to achieve this necessary balance.
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B.

Canada
The NAPRA’s strict standards for facility design and equipment
for sterile compounding have resulted in costly and time consuming
renovation for many compounding facilities.237 Regarding facility
design, some of the requirements include the following:
1. A reserved area large enough for sterile preparations – ensure good flow of people, equipment and materials; and allow disinfecting and cleaning without constraint.238
2. Heating, ventilation, and air conditioning systems must be
designed to minimize risk of airborne contamination in controlled
rooms.239 Specifically return air intakes must be placed at the bottom
of the walls to push any possible contaminants downward.240
3. Controlled rooms must not have any windows or openings
that lead to the outside or non-controlled rooms.241 If they do, they
must be sealed.242
4. A clean room, where atmospheric properties are controlled.243
5. An anteroom, which is the transition space between a noncontrolled and controlled room.244
According to Sabrina McLean, a pharmacist and compounding
consultant in Dartmouth, Nova Scotia, some pharmacies producing
sterile compounds “would have to do full renovations to meet the
requirements.”245 In achieving these lofty goals, some of these pharmacies have discontinued operations, while others have been forced
to decrease production significantly.246 Lawtons, a Nova Scotia
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pharmacy that participates in compounding, has dramatically decreased its compounding activity as an alternative to major facility
renovations based on the new regulations.247 Unfortunately, Canadian consumers, just like their peers in the U.S., may have no choice
but to incur higher costs for their compounded drugs or simply do
without as many pharmaceutical compounding companies are being
overregulated out of the market.
Canada has not seen the full impact of the new regulations on
drug prices and availability simply because the NAPRA has recently
published the Model Standards for Non-Sterile Preparations.248 It is
McLean’s assertion that the new regulations for non-sterile compounding will require the use of more expensive protective equipment.249 While it is reasonable to speculate that the costs associated
around non-sterile compounding will only be a small percentage
compared to what it is for sterile compounding, costs may still be
high enough to deter pharmacies from producing non-sterile compounds.
On the other hand, even with the NAPRA Model Standards
largely increasing the overhead costs, some compounding pharmacies are not struggling with offsetting these high costs due to generous dispensing and compounding fee subsidized payments by provincial drugs programs.250 In August 2017, Manitoba placed a $30
cap on compounding fee payments for non-sterile compounded
drugs and a $60 cap for sterile compounded drugs per prescription.251 Because pharmacies individually determine dispensing and
compounding fees, clients became concerned that they would be required to pay additional fees above and beyond the payment caps.252
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This was especially true for compounded drugs that could cost hundreds of dollars to produce.253 Quinton Didyk, an owner of a compounding pharmacy that serves over half of the pharmacies in Manitoba, asserts that his customers will not be charged additional compounding fees due to the generous payment caps.254 Additionally,
the policy contains an exemption clause which states that specialty
compounds or compounds that take more than forty-five minutes to
prepare will be subsidized by provincial drug programs.255 These
regulated compounding fee payments allow compounding pharmacies to remain competitive and profitable while keeping prices affordable.
These fee payments are not quite as generous in other provinces.256 Most provinces have dispensing fee payment caps around
$8-12.257 For example, Ontario has a cap starting at $8.83 and goes
up to $13.25 depending on the location.258 With such low payment
caps, compounding facilities in other provinces are forced to choose
whether to remain competitive, but less profitable, or gamble by
charging higher fees which would require consumers to reach in
their pockets. In the end, the latter choice may likely lead to a less
profitable outcome as consumers may seek other sources of remediation. Should provinces decide to increase or match the payment
caps set in Manitoba, compounding pharmacies would find it more
financially feasible to remain and comply with the NAPRA Model
Standards, thereby keeping compounded drugs available and affordable to consumers throughout Canada.
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VI.
CONCLUSION
With an ever-increasing population, drug shortages, and a growing need for customized medications, drug compounding will continue to be an essential component in the world of pharmaceuticals.
While these drugs are desperately needed to fill the void in the market, the business of pharmaceutical compounding remains dangerous and, for the most part, unregulated in the U.S. despite Congress’
passing of the Drug Quality and Safety Act, which defines state and
federal authority and responsibilities in order to ensure consumer
safety.259 This has left many gaps in the regulatory framework, allowing sterile compounding pharmacies to function unchecked and
unaccountable.260 Incommensurable standards of quality and requirements for training between states, in conjunction with misaligned state and federal laws and regulations, continues to be the
greatest impediment in the delivery of safe and high quality pharmaceuticals.261 Moreover, Congress tied the FDA’s hands when it
opted against mandating outsourcing facilities from having to register with the FDA.262 The FDA cannot effectively regulate outsourcing facilities when states undermine the incentives the FDA provides to voluntarily register.263 At the same time, states that enforce
regulations set by the Drug Quality and Safety Act have made it less
financially viable for traditional compounding pharmacies due to
strict scrutiny over sterile compounding practices and procedures.264
Some pharmacies have chosen to drastically reduce the number of
compounded drugs produced, while others have simply ceased operations.265 Ultimately, consumers of drug compounds have less
availability, are faced with higher prices, and remain vulnerable to
potentially unsafe medications.
Similarly, Canadian pharmaceutical compounding continues to
play a crucial role in the healthcare system. While it remains to be
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seen whether the NAPRA Model Standards will be effective in ensuring consumer safety, the NAPRA has clearly placed the responsibility into the hands of pharmacy professionals.266 Unlike the
Compounding Quality Act in the U.S., the Model Standards provide
compounding pharmacies with detailed guidelines in the preparation
of compounds.267 These clear and concise guidelines allow provincial/territorial authorities to easily enforce and maintain these high
standards.268 On the negative side, however, while the enforcement
of such rigid NAPRA Model Standards maintains high compounding quality standards, costs are driven up by the requirements for
upgraded facility design, sophisticated equipment, and better trained
personnel.269 Dramatically higher production costs have already
driven several Canadian compounding pharmacies out of the market.270 However, provinces may be able to find ways to incentivize
pharmacies, thereby offsetting the costly changes required by the
Model Standards.271 Raising compounding fee payment caps would
be an effective method of achieving this goal. With a bit of tweaking
and creativity, Canada’s regulatory initiatives appear to hold the
most promise for procuring safe drug compounds without the risk of
diminished availability or exorbitant prices.
The U.S. and Canada face a future which will require additional governmental action to secure the successful delivery of quality compounded medications. As noted by Michael Carome, MD,
director of the Public Citizen Health Research Group in Washington, DC, “[a]lthough compounded drugs serve an important need for
patients whose medical needs cannot be met by an FDA-approved
drug, it is imperative that healthcare providers and patients alike recognize that compounded drugs pose a higher risk to patients than
FDA-approved products.”272 Whether additional federal legislation
is needed to bring compounded drugs up to FDA-approved stand-
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ards is a relevant question. In either case, a close working relationship between federal and state/provincial levels must exist for compounding to successfully and safely coexist with traditional pharmaceutical manufacturers. While both countries have made headway
into developing effective strategies to accomplish these goals, collaboration, creativity, and a broad-minded willingness of state or
provincial/territorial and federal governments to work together for
the good of public health will be key to making compounding pharmacies profitable, safe, and able to meet the future demands of an
ever-growing population.

